Anti-tumor vaccines in head and neck cancer: Targeting immune responses to the tumor

Current Cancer Drug Targets

Volumn 7, Issue 7, 2007, Pages 633-642

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Dendritic cells; Head and neck cancer; Immunization; Tumor escape; Vaccines

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CD83 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DENDRITIC CELL VACCINE; EPITOPE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7; MELANOMA ANTIGEN 3; PROSTAGLANDIN E2; PROTEIN P53; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR VACCINE;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DENDRITIC CELL; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IN VIVO STUDY; MINIMAL RESIDUAL DISEASE; NATURAL KILLER CELL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY;

CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOLOGIC MEMORY; T-LYMPHOCYTES;

EID: 35948968823     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907782418310     Document Type: Review

References (145)

1. Novellino, L.; Castelli, C.; Parmiani, G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 2005, 54, 187-207.
2. Rosenberg, S. A.; Yang, J. C.; Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10, 909-915.
3. Houghton, A. N.; Guevara-Patino, J. A. Immune recognition of self in immunity against cancer. J. Clin. Invest. 2004, 114, 468-471.
4. Srivastava, P. K. Therapeutic cancer vaccines. Curr. Opin. Immunol. 2006, 18, 201-205.
5. Mao, L.; Hong, W. K.; Papadimitrakopoulou, V. A. Focus on head and neck cancer. Cancer Cell 2004, 5, 311-316.
6. McMahon, S.; Chen, A. Y. Head and neck cancer. Cancer Metastasis Rev. 2003, 22, 21-24.
7. Vokes, E. E.; Weichselbaum, R. R.; Lippman, S. M.; Hong, W. K. Head and neck cancer. N. Engl. J. Med. 1993, 328, 184-194.
8. Cohen, E. E.; Lingen, M. W.; Vokes, E. E. The expanding role of systemic therapy in head and neck cancer. J. Clin. Oncol. 2004, 22, 1743-1752.
9. Bernier, J.; Domenge, C.; Ozsahin, M.; Matuszewska, K.; Lefebvre, J. L.; Greiner, R. H.; Giralt, J.; Maingon, P.; Rolland, F.; Bolla, M.; Cognetti, F.; Bourhis, J.; Kirkpatrick, A.; van Glabbeke, M. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 2004, 350, 1945-1952.
10. Cooper, J. S.; Pajak, T. F.; Forastiere, A. A.; Jacobs, J.; Campbell, B. H.; Saxman, S. B.; Kish, J. A.; Kim, H. E.; Cmelak, A. J.; Rotman, M.; Machtay, M.; Ensley, J. F.; Chao, K. S.; Schultz, C. J.; Lee, N.; Fu, K. K. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2004, 350, 1937-1944.
11. Ford, A. C.; Grandis, J. R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003, 25, 67-73.
12. Pomerantz, R. G.; Grandis, J. R. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma. Curr. Oncol. Rep. 2003, 5, 140-146.
13. Whiteside, T. Tumor-infiltrating lymphocytes in head and neck cancer. In: Immunotherapy of Cancer with Sensitized T Lymphocytes. 1994, 133-154.
14. Hald, J.; Rasmussen, N.; Claesson, M. H. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol. Immunother. 1995, 41, 243-250.
15. Reichert, T. E.; Day, R.; Wagner, E. M.; Whiteside, T. L. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998, 58, 5344-5347.
16. Hoffmann, T. K.; Donnenberg, A. D.; Finkelstein, S. D.; Donnenberg, V. S.; Friebe-Hoffmann, U.; Myers, E. N.; Appella, E.; DeLeo, A. B.; Whiteside, T. L. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res. 2002, 62, 3521-3529.
17. Bourhis, J.; Lubin, R.; Roche, B.; Koscielny, S.; Bosq, J.; Dubois, I.; Talbot, M.; Marandas, P.; Schwaab, G.; Wibault, P.; Luboinski, B.; Eschwege, F.; Soussi, T. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 1996, 88, 1228-1233.
18. Kraunz, K. S.; McClean, M. D.; Nelson, H. H.; Peters, E.; Calderon, H.; Kelsey, K. T. Duration but not intensity of alcohol and tobacco exposure predicts p16INK4A homozygous deletion in head and neck squamous cell carcinoma. Cancer Res. 2006, 66, 4512-4515.
19. Zhang, Z. F.; Morgenstern, H.; Spitz, M. R.; Tashkin, D. P.; Yu, G. P.; Hsu, T. C.; Schantz, S. P. Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 1043-1049.
20. Schantz, S. P.; Zhang, Z. F.; Spitz, M. S.; Sun, M.; Hsu, T. C. Genetic susceptibility to head and neck cancer: interaction between nutrition and mutagen sensitivity. Laryngoscope 1997, 107, 765-781.
21. Tanabe, H.; Yokota, K.; Shibata, N.; Satoh, T.; Watari, J.; Kohgo, Y. Alcohol consumption as a major risk factor in the development of early esophageal cancer in patients with head and neck cancer. Intern. Med. 2001, 40, 692-696.
22. Whiteside, T. L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16, 3-15.
23. Whiteside, T. L. Immunobiology of head and neck cancer. Cancer Metastasis Rev. 2005, 24, 95-105.
24. Hadden, J. W. The immunopharmacology of head and neck cancer: an update. Int. J. Immunopharmacol. 1997, 19, 629-644.
25. Wanebo, H. J.; Hilal, E. Y.; Strong, E. W.; Pinsky, C. M.; Mike, V.; Oettgen, H. F. Adjuvant trial of levamisole in patients with squamous cancer of the head and neck: a preliminary report. Recent Results Cancer Res. 1978, 68, 324-333.
26. Young, M. R.; Wright, M. A.; Lozano, Y.; Matthews, J. P.; Benefield, J.; Prechel, M. M. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer 1996, 67, 333-338.
27. Whiteside, T. L. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol. Immunother. 1999, 48, 346-352.
28. Reichert, T. E.; Strauss, L.; Wagner, E. M.; Gooding, W.; Whiteside, T. L. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin. Cancer Res. 2002, 8, 3137-3145.
29. Reichert, T. E.; Rabinowich, H.; Johnson, J. T.; Whiteside, T. L. Mechanisms responsible for signaling and functional defects. J. Immunother. 1998, 21, 295-306.
30. Lang, S.; Whiteside, T. L.; Lebeau, A.; Zeidler, R.; Mack, B.; Wollenberg, B. Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch. Otolaryngol. Head Neck Surg. 1999, 125, 82-88.
31. Kim, J.; Modlin, R. L.; Moy, R. L.; Dubinett, S. M.; McHugh, T.; Nickoloff, B. J.; Uyemura, K. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J. Immunol. 1995, 155, 2240-2247.
32. Kim, J. W.; Wieckowski, E.; Taylor, D. D.; Reichert, T. E.; Watkins, S.; Whiteside, T. L. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 2005, 11, 1010-1020.
33. Maca, R. D. The effects of prostaglandins on the proliferation of cultured human T lymphocytes. Immunopharmacology 1983, 6, 267-277.
34. Snyderman, C. H.; Klapan, I.; Milanovich, M.; Heo, D. S.; Wagner, R.; Schwartz, D.; Johnson, J. T.; Whiteside, T. L. Comparison of in vivo and in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. Otolaryngol. Head Neck Surg. 1994, 111, 189-196.
35. Simons, P. J.; Oostendorp, R. A.; Tas, M. P.; Drexhage, H. A. Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer. Cancer Immunol. Immunother. 1994, 38, 178-184.
36. Berlinger, N. T. Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 1984, 94, 1407-1410.
37. Hoffmann, T. K.; Dworacki, G.; Tsukihiro, T.; Meidenbauer, N.; Gooding, W.; Johnson, J. T.; Whiteside, T. L. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin. Cancer Res. 2002, 8, 2553-2562.
38. Bauernhofer, T.; Kuss, I.; Henderson, B.; Baum, A. S.; Whiteside, T. L. Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer. Eur. J. Immunol. 2003, 33, 119-124.
39. Ferris, R. L.; Whiteside, T. L.; Ferrone, S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin. Cancer Res. 2006, 12, 3890-3895.
40. Molling, J. W.; Kolgen, W.; van der Vliet, H. J.; Boomsma, M. F.; Kruizenga, H.; Smorenburg, C. H.; Molenkamp, B. G.; Langendijk, J. A.; Leemans, C. R.; von Blomberg, B. M.; Scheper, R. J.; van den Eertwegh, A. J. Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 2005, 116, 87-93.
41. Kuss, I.; Hathaway, B.; Ferris, R. L.; Gooding, W.; Whiteside, T. L. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2004, 10, 3755-3762.
42. Tsukishiro, T.; Donnenberg, A. D.; Whiteside, T. L. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol. Immunother. 2003, 52, 599-607.
43. Albers, A. E.; Ferris, R. L.; Kim, G. G.; Chikamatsu, K.; DeLeo, A. B.; Whiteside, T. L. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol. Immunother. 2005, 54, 1072-1081.
44. Schaefer, C.; Kim, G. G.; Albers, A.; Hoermann, K.; Myers, E. N.; Whiteside, T. L. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 2005, 92, 913-920.
45. Beyer, M.; Kochanek, M.; Darabi, K.; Popov, A.; Jensen, M.; Endl, E.; Knolle, P. A.; Thomas, R. K.; von Bergwelt-Baildon, M.; Debey, S.; Hallek, M.; Schultze, J. L. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106, 2018-2025.
46. Dannull, J.; Su, Z.; Rizzieri, D.; Yang, B. K.; Coleman, D.; Yancey, D.; Zhang, A.; Dahm, P.; Chao, N.; Gilboa, E.; Vieweg, J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005, 115, 3623-3633.
47. Whiteside, T. L. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol. Immunother. 2004, 53, 865-878.
48. Reichert, T. E.; Scheuer, C.; Day, R.; Wagner, W.; Whiteside, T. L. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001, 91, 2136-2147.
49. Lou, Y.; Vitalis, T. Z.; Basha, G.; Cai, B.; Chen, S. S.; Choi, K. B.; Jeffries, A. P.; Elliott, W. M.; Atkins, D.; Seliger, B.; Jefferies, W. A. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res. 2005, 65, 7926-7933.
50. Meissner, M.; Reichert, T. E.; Kunkel, M.; Gooding, W.; Whiteside, T. L.; Ferrone, S.; Seliger, B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin. Cancer Res. 2005, 11, 2552-2560.
51. Young, M. R. Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 2004, 53, 375-382.
52. Hoffmann, T. K.; Bier, H.; Whiteside, T. L. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck. Cancer Immunol. Immunother. 2004, 53, 1055-1067.
53. Ito, D.; Albers, A.; Zhao, Y. X.; Visus, C.; Appella, E.; Whtieside, T. L.; DeLeo, A. B. The wild type sequences p5325-35 peptide induces HLA-DR7 and HLA-DR11-restricted CD4+ T helper cells capable of enhancing the ex vivo expansion and function of anti-wild type sequence p53264-272 peptide CD8+ T cells. J. Immunol. 2006, 177(10), 6795-6803.
54. Kienstra, M. A.; Neel, H. B.; Strome, S. E.; Roche, P. Identification of NYESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003, 25, 457-463.
55. Figueiredo, D. L.; Mamede, R. C.; Proto-Siqueira, R.; Neder, L.; Silva, W. A. Jr.; Zago, M. A. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 2006, 28, 614-619.
56. Eura, M.; Ogi, K.; Chikamatsu, K.; Lee, K. D.; Nakano, K.; Masuyama, K.; Itoh, K.; Ishikawa, T. Expression of the MAGE gene family in human headand-neck squamous-cell carcinomas. Int. J. Cancer 1995, 64, 304-308.
57. Gotte, K.; Usener, D.; Riedel, F.; Hormann, K.; Schadendorf, D.; Eichmuller, S. Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes. Acta Otolaryngol. 2002, 122, 546-552.
58. Ries, J.; Schultze-Mosgau, S.; Neukam, F.; Diebel, E.; Wiltfang, J. Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to -A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J. Oncol. 2005, 26, 817-824.
59. Simpson, A. J.; Caballero, O. L.; Jungbluth, A.; Chen, Y. T.; Old, L. J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5, 615-625.
60. Balz, V.; Scheckenbach, K.; Gotte, K.; Bockmuhl, U.; Petersen, I.; Bier, H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res. 2003, 63, 1188-1191.
61. Boyle, J. O.; Hakim, J.; Koch, W.; van der Riet, P.; Hruban, R. H.; Roa, R. A.; Correo, R.; Eby, Y. J.; Ruppert, J. M.; Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993, 53, 4477-4480.
62. Chikamatsu, K.; Albers, A.; Stanson, J.; Kwok, W. W.; Appella, E.; Whiteside, T. L.; DeLeo, A. B. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res. 2003, 63, 3675-3681.
63. Chikamatsu, K.; Nakano, K.; Storkus, W. J.; Appella, E.; Lotze, M. T.; Whiteside, T. L.; DeLeo, A. B. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res. 1999, 5, 1281-1288.
64. Offringa, R.; Vierboom, M. P.; van der Burg, S. H.; Erdile, L.; Melief, C. J. p53: a potential target antigen for immunotherapy of cancer. Ann. N Y Acad. Sci. 2000, 910, 223-233; discussion 233-226.
65. Hoffmann, T. K.; Nakano, K.; Elder, E. M.; Dworacki, G.; Finkelstein, S. D.; Appella, E.; Whiteside, T. L.; DeLeo, A. B. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J. Immunol. 2000, 165, 5938-5944.
66. Hoffmann, T. K.; Loftus, D. J.; Nakano, K.; Maeurer, M. J.; Chikamatsu, K.; Appella, E.; Whiteside, T. L.; DeLeo, A. B. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J. Immunol. 2002, 168, 1338-1347.
67. Kao, H.; Marto, J. A.; Hoffmann, T. K.; Shabanowitz, J.; Finkelstein, S. D.; Whiteside, T. L.; Hunt, D. F.; Finn, O. J. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J. Exp. Med. 2001, 194, 1313-1323.
68. Egloff, A. M.; Vella, L. A.; Finn, O. J. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res. 2006, 66, 6-9.
69. Shimizu, K.; Yamaguchi, Y.; Ohta, K.; Miyahara, E.; Toge, T. Analysis of T cell receptors reactive with squamous cell carcinoma antigen SART-1 presented by the HLA-A24 molecule. Oncol. Rep. 2002, 9, 599-605.
70. Nakao, M.; Shichijo, S.; Imaizumi, T.; Inoue, Y.; Matsunaga, K.; Yamada, A.; Kikuchi, M.; Tsuda, N.; Ohta, K.; Takamori, S.; Yamana, H.; Fujita, H.; Itoh, K. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J. Immunol. 2000, 164, 2565-2574.
71. Shichijo, S.; Nakao, M.; Imai, Y.; Takasu, H.; Kawamoto, M.; Niiya, F.; Yang, D.; Toh, Y.; Yamana, H.; Itoh, K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med. 1998, 187, 277-288.
72. Ito, M.; Shichijo, S.; Miyagi, Y.; Kobayashi, T.; Tsuda, N.; Yamada, A.; Saito, N.; Itoh, K. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int. J. Cancer 2000, 88, 633-639.
73. Lo Muzio, L.; Pannone, G.; Staibano, S.; Mignogna, M. D.; Rubini, C.; Mariggio, M. A.; Procaccini, M.; Ferrari, F.; De Rosa, G.; Altieri, D. C. Survivin expression in oral squamous cell carcinoma. Br. J. Cancer 2003, 89, 2244-2248.
74. Lo Muzio, L.; Campisi, G.; Giovannelli, L.; Ammatuna, P.; Greco, I.; Staibano, S.; Pannone, G.; De Rosa, G.; Di Liberto, C.; D'Angelo, M. HPV DNA and survivin expression in epithelial oral carcinogenesis: a relationship? Oral Oncol. 2004, 40, 736-741.
75. Lo Muzio, L.; Staibano, S.; Pannone, G.; Mignogna, M. D.; Mariggio, A.; Salvatore, G.; Chieffi, P.; Tramontano, D.; De Rosa, G.; Altieri, D. C. Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp. Mol. Pathol. 2001, 70, 249-254.
76. Jaattela, M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 1999, 248, 30-43.
77. Weinman, E. C.; Roche, P. C.; Kasperbauer, J. L.; Cha, S. S.; Sargent, D. J.; Cheville, J.; Murphy, L. M.; Chen, L.; Wettstein, P. J.; Gostout, B.; Ferrone, S.; Strome, S. E. Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Cancer 2003, 97, 2203-2211.
78. Reker, S.; Meier, A.; Holten-Andersen, L.; Svane, I. M.; Becker, J. C.; thor Straten, P.; Andersen, M. H. Identification of novel survivin-derived CTL epitopes. Cancer Biol. Ther. 2004, 3, 173-179.
79. Altieri, D. C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3, 46-54.
80. Disis, M. L.; Gooley, T. A.; Rinn, K.; Davis, D.; Piepkorn, M.; Cheever, M. A.; Knutson, K. L.; Schiffman, K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 2002, 20, 2624-2632.
81. Kass, E. S.; Greiner, J. W.; Kantor, J. A.; Tsang, K. Y.; Guadagni, F.; Chen, Z.; Clark, B.; De Pascalis, R.; Schlom, J.; Van Waes, C. Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res. 2002, 62, 5049-5057.
82. Visus, C.; Whiteside, T. L.; DeLeo, A. B. Identification and characterization of a novel HLA-A*0201-restricted T-cell defined antigen in human head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 838.
83. Elizondo, G.; Corchero, J.; Sterneck, E.; Gonzalez, F. J. Feedback inhibition of the retinaldehyde dehydrogenase gene ALDH1 by retinoic acid through retinoic acid receptor alpha and CCAAT/enhancer-binding protein beta. J. Biol. Chem. 2000, 275, 39747-39753.
84. Kastan, M. B.; Schlaffer, E.; Russo, J. E.; Colvin, O. M.; Civin, C. I.; Hilton, J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990, 75, 1947-1950.
85. Asai, T.; Storkus, W. J.; Mueller-Berghaus, J.; Knapp, W.; DeLeo, A. B.; Chikamatsu, K.; Whiteside, T. L. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun. 2002, 2, 3.
86. Corti, S.; Locatelli, F.; Papadimitriou, D.; Donadoni, C.; Salani, S.; Del Bo, R.; Strazzer, S.; Bresolin, N.; Comi, G. P. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 2006, 24, 975-985.
87. Bonehill, A.; Heirman, C.; Thielemans, K. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. J. Gene Med. 2005, 7, 686-695.
88. Nestle, F. O.; Farkas, A.; Conrad, C. Dendritic-cell-based therapeutic vaccination against cancer. Curr. Opin. Immunol. 2005, 17, 163-169.
89. Banchereau, J.; Palucka, A. K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 2005, 5, 296-306.
90. Almand, B.; Clark, J. I.; Nikitina, E.; van Beynen, J.; English, N. R.; Knight, S. C.; Carbone, D. P.; Gabrilovich, D. I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166, 678-689.
91. Almand, B.; Resser, J. R.; Lindman, B.; Nadaf, S.; Clark, J. I.; Kwon, E. D.; Carbone, D. P.; Gabrilovich, D. I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6, 1755-1766.
92. Hoffmann, T. K.; Muller-Berghaus, J.; Ferris, R. L.; Johnson, J. T.; Storkus, W. J.; Whiteside, T. L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin. Cancer Res. 2002, 8, 1787-1793.
93. Berger, T. G.; Strasser, E.; Smith, R.; Carste, C.; Schuler-Thurner, B.; Kaempgen, E.; Schuler, G. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J. Immunol. Methods 2005, 298, 61-72.
94. Peng, J. C.; Thomas, R.; Nielsen, L. K. Generation and maturation of dendritic cells for clinical application under serum-free conditions. J. Immunother. 2005, 28, 599-609.
95. Mailliard, R. B.; Egawa, S.; Cai, Q.; Kalinska, A.; Bykovskaya, S. N.; Lotze, M. T.; Kapsenberg, M. L.; Storkus, W. J.; Kalinski, P. Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J. Exp. Med. 2002, 195, 473-483.
96. Hoffmann, T. K.; Meidenbauer, N.; Dworacki, G.; Kanaya, H.; Whiteside, T. L. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000, 60, 3542-3549.
97. Boczkowski, D.; Nair, S. K.; Nam, J. H.; Lyerly, H. K.; Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000, 60, 1028-1034.
98. Whiteside, T. L.; Gambotto, A.; Albers, A.; Stanson, J.; Cohen, E. P. Human tumor-derived genomic DNA transduced into a recipient cell induces tumorspecific immune responses ex vivo. Proc. Natl. Acad. Sci. USA 2002, 99, 9415-9420.
99. Artusio, E.; Hathaway, B.; Stanson, J.; Whiteside, T. L. Transfection of human monocyte-derived dendritic cells wit native tumor DNA induces antigen-specific T cell responses in vitro. Cancer Biol. Ther. 2006, 5(12), 1624-1631.
100. Dorfel, D.; Appel, S.; Grunebach, F.; Weck, M. M.; Muller, M. R.; Heine, A.; Brossart, P. Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. Blood 2005, 105, 3199-3205.
101. Bonehill, A.; Heirman, C.; Tuyaerts, S.; Michiels, A.; Breckpot, K.; Brasseur, F.; Zhang, Y.; Van Der Bruggen, P.; Thielemans, K. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 2004, 172, 6649-6657.
102. Jonuleit, H.; Giesecke-Tuettenberg, A.; Tuting, T.; Thurner-Schuler, B.; Stuge, T. B.; Paragnik, L.; Kandemir, A.; Lee, P. P.; Schuler, G.; Knop, J.; Enk, A. H. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 2001, 93, 243-251.
103. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3, 133-146.
104. de Vries, I. J.; Lesterhuis, W. J.; Scharenborg, N. M.; Engelen, L. P.; Ruiter, D. J.; Gerritsen, M. J.; Croockewit, S.; Britten, C. M.; Torensma, R.; Adema, G. J.; Figdor, C. G.; Punt, C. J. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 2003, 9, 5091-5100.
105. Adema, G. J.; de Vries, I. J.; Punt, C. J.; Figdor, C. G. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol. 2005, 17, 170-174.
106. Figdor, C. G.; de Vries, I. J.; Lesterhuis, W. J.; Melief, C. J. Dendritic cell immunotherapy: mapping the way. Nat. Med. 2004, 10, 475-480.
107. Whiteside, T.; Ferris, R. L.; Myers, E. N.; Tublin, M.; Kiss, J.; Johnson, R.; Johnson, J. T. Dendritic cell (DC)-based vaccine for patients with SCCHN using autologous tumor cells as immunogens. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 840.
108. Cohen, E. P. Cancer therapy with DNA-based vaccines. Immunol. Lett. 2000, 74, 59-65.
109. O. Sullivan, I.; Kim, T. S.; Chopra, A.; Cohen, E. P. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma. Anticancer Res. 2006, 26, 873-884.
110. Chopra, A.; Kim, T. S.; I, O. S.; Martinez, D.; Cohen, E. P. Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma-a new vaccination strategy. Int. J. Cancer 2006, 119, 339-348.
111. Ferris, R.; DeLeo, A. B.; Whiteside, T. L. Adjuvant p53 peptide loaded DC-based therapy of subjects with squamous cell cancer of the head and neck (a phase I safety and immunogenicity trial). UPCI protocol, Pittsburgh, PA, 2006.
112. Karcher, J.; Dyckhoff, G.; Beckhove, P.; Reisser, C.; Brysch, M.; Ziouta, Y.; Helmke, B. H.; Weidauer, H.; Schirrmacher, V.; Herold-Mende, C. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004, 64, 8057-8061.
113. Herold-Mende, C.; Karcher, J.; Dyckhoff, G.; Schirrmacher, V. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. Adv. Otorhinolaryngol. 2005, 62, 173-183.
114. To, W. C.; Wood, B. G.; Krauss, J. C.; Strome, M.; Esclamado, R. M.; Lavertu, P.; Dasko, D.; Kim, J. A.; Plautz, G. E.; Leff, B. E.; Smith, V.; Sandstrom-Wakeling, K.; Shu, S. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch. Otolaryngol. Head Neck Surg. 2000, 126, 1225-1231.
115. Rosenberg, S. A.; Yannelli, J. R.; Yang, J. C.; Topalian, S. L.; Schwartzentruber, D. J.; Weber, J. S.; Parkinson, D. R.; Seipp, C. A.; Einhorn, J. H.; White, D. E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86, 1159-1166.
116. Whiteside, T. L. Tumor-infiltrating lymphocytes in human solid tumors. Immunol. Ser. 1994, 61, 137-148.
117. Whiteside, T. L.; Heo, D. S.; Takagi, S.; Herberman, R. B. Characterization of novel anti-tumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes. Transplant Proc. 1988, 20, 347-350.
118. Yasumura, S.; Hirabayashi, H.; Schwartz, D. R.; Toso, J. F.; Johnson, J. T.; Herberman, R. B.; Whiteside, T. L. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res. 1993, 53, 1461-1468.
119. Letessier, E. M.; Sacchi, M.; Johnson, J. T.; Herberman, R. B.; Whiteside, T. L. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol. 1990, 130, 446-458.
120. Boscia, R.; Chen, K.; Johnson, J. T.; Whiteside, T. L. Evaluation of therapeutic potential of interleukin 2-expanded tumor-infiltrating lymphocytes in squamous cell carcinoma of the head and neck. Ann. Otol. Rhinol. Laryngol. 1988, 97, 414-421.
121. Yamamoto, T.; Yoneda, K.; Ueta, E.; Doi, S.; Osaki, T. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur. J. Cancer 2000, 36, 2007-2017.
122. Ikawa, T.; Eura, M.; Fukiage, T.; Murakami, H.; Yamasaki, S.; Fukuda, K.; Fukushima, M.; Arishima, S.; Maehara, T.; Ishikawa, T. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer]. Gan To Kagaku Ryoho 1989, 16, 1438-1447.
123. Ishikawa, T.; Ikawa, T.; Eura, M.; Fukiage, T.; Masuyama, K. Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2. Acta Otolaryngol. 1989, 107, 346-351.
124. Squadrelli-Saraceno, M.; Rivoltini, L.; Cantu, G.; Ravagnani, F.; Parmiani, G.; Molinari, R. Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori 1990, 76, 566-571.
125. Kubota, E.; Katano, M.; Kurokawa, H.; Imamura, H.; Katsuki, T.; Yamamoto, H.; Hisatsugu, T.; Nagumo, F.; Tadano, J. Tumoricidal effect of human PBMC following stimulation with OK-432 and its application for locoregional immunotherapy in head and neck cancer patients. J. Craniomaxillofac Surg. 1993, 21, 30-37.
126. Gattinoni, L.; Finkelstein, S. E.; Klebanoff, C. A.; Antony, P. A.; Palmer, D. C.; Spiess, P. J.; Hwang, L. N.; Yu, Z.; Wrzesinski, C.; Heimann, D. M.; Surh, C. D.; Rosenberg, S. A.; Restifo, N. P. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202, 907-912.
127. Huang, J.; Khong, H. T.; Dudley, M. E.; El-Gamil, M.; Li, Y. F.; Rosenberg, S. A.; Robbins, P. F. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 2005, 28, 258-267.
128. Dudley, M. E.; Wunderlich, J. R.; Yang, J. C.; Sherry, R. M.; Topalian, S. L.; Restifo, N. P.; Royal, R. E.; Kammula, U.; White, D. E.; Mavroukakis, S. A.; Rogers, L. J.; Gracia, G. J.; Jones, S. A.; Mangiameli, D. P.; Pelletier, M. M.; Gea-Banacloche, J.; Robinson, M. R.; Berman, D. M.; Filie, A. C.; Abati, A.; Rosenberg, S. A. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23, 2346-2357.
129. Ling, W.; Rayman, P.; Uzzo, R.; Clark, P.; Kim, H. J.; Tubbs, R.; Novick, A.; Bukowski, R.; Hamilton, T.; Finke, J. Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalpha. Blood 1998, 92, 1334-1341.
130. Campbell, K. J.; Perkins, N. D. Regulation of NF-kappaB function. Biochem. Soc. Symp. 2006, 165-180.
131. Whiteside, T. L. The role of death receptor ligands in shaping tumor microenvironment. Immunol. Invest. 2007, 36(1), 25-46.
132. Whiteside, T. L.; Stanson, J.; Shurin, M. R.; Ferrone, S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and downregulation by tumor cells. J. Immunol. 2004, 173, 1526-1534.
133. Tourkova, I. L.; Shurin, G. V.; Chatta, G. S.; Perez, L.; Finke, J.; Whiteside, T. L.; Ferrone, S.; Shurin, M. R. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J. Immunol. 2005, 175, 3045-3052.
134. Esche, C.; Shurin, G. V.; Kirkwood, J. M.; Wang, G. Q.; Rabinowich, H.; Pirtskhalaishvili, G.; Shurin, M. R. Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin. Cancer Res. 2001, 7, 974s-979s.
135. Wang, S.; Chen, L. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect. 2004, 6, 759-766.
136. Baecher-Allan, C.; Anderson, D. E. Immune regulation in tumor-bearing hosts. Curr. Opin. Immunol. 2006, 18, 214-219.
137. Serafini, P.; Borrello, I.; Bronte, V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. Cancer Biol. 2006, 16, 53-65.
138. Pak, A. S.; Wright, M. A.; Matthews, J. P.; Collins, S. L.; Petruzzelli, G. J.; Young, M. R. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1995, 1, 95-103.
139. Saito, T.; Kuss, I.; Dworacki, G.; Gooding, W.; Johnson, J. T.; Whiteside, T. L. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin. Cancer Res. 1999, 5, 1263-1273.
140. Whiteside, T. L. Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? Br. J. Cancer 2005, 92, 209-211.
141. Whiteside, T.; Campoli, M.; Ferrone, S. Tumor induced immune suppression and immune escape: mechanisms and possible solutions. In: Analyzing T Cell Responses; Nagorsen, D.; Marincola, F. M., Eds., Springer Publishers: 2005, pp. 43-82.
142. Seliger, B.; Cabrera, T.; Garrido, F.; Ferrone, S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin. Cancer Biol. 2002, 12, 3-13.
143. Schantz, S. P.; Ordonez, N. G. Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer.
144. Malmberg, K. J.; Ljunggren, H. G. Escape from immune- and nonimmunemediated tumor surveillance. Semin. Cancer Biol. 2006, 16, 16-31.
145. Bjerkvig, R.; Tysnes, B. B.; Aboody, K. S.; Najbauer, J.; Terzis, A. J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat. Rev. Cancer 2005, 5, 899-904.